摘要
近年来,临床心力衰竭诊断率逐年提高,但心力衰竭患者5年生存率改善效果有限。沙库巴曲缬沙坦作为目前世界上唯一在临床应用的血管紧张素受体脑啡肽酶抑制剂,能有效降低多种原因引起的心力衰竭患者再住院率及心血管死亡风险,目前其已被国内外众多临床指南列为Ⅰ类推荐。本文主要综述了沙库巴曲缬沙坦治疗心力衰竭及心力衰竭合并其他常见疾病的研究进展,以期为临床合理应用该药提供参考。
Clinical diagnosis rate of heart failure increased year by year in recent years,however five-year survival rate in patients with heart failure improved finitely. Sacubitril/Valsartan,as the only angiotensin receptor neprilysin inhibitor that applied on clinic all over the world,can effectively reduce the re-hospitalization rate and cardiovascular death risk in patients with heart failure that caused by various reasons,moreover it has been classified as Ⅰ-class recommendation by numerous clinical guidelines at home and abroad so far. This paper mainly reviewed the research progress about Sacubitril/Valsartan in treating heart failure and even heart failure merged with other common diseases,in order to provide a reference for its rational clinical use.
作者
王晓雪
孙维
宁亚媛
陈丽娟
WANG Xiaoxue(Department of Cardiovascular Medicine,the Second Hospital of Jilin University,Changchun 130041,China)
出处
《实用心脑肺血管病杂志》
2020年第1期8-11,共4页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
